<PAGE> 1
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): February 16, 1998
BIONUTRICS, INC.
(Exact name of registrant as specified in its charter)
Commission File Number: 0-22011
NEVADA 86-0760991
(State or other jurisdiction of (IRS Employer
incorporation or organization) Identification No.)
2425 E. CAMELBACK RD., SUITE 650
PHOENIX, AZ 85016-4214
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: 602-508-0112
<PAGE> 2
Item 5. Other Events
Effective February 16, 1998, registrant and Novartis Nutrition AG, Bern,
Switzerland, entered into an agreement for a strategic alliance to conduct an
evaluation of registrant's technology relating to rice bran derivatives for
purposes of developing functional food ingredients that effect biological
activities. Pursuant to the agreement, Novartis has made an initial equity
investment in registrant of $3 million at $7.25 per share.
<PAGE> 3
BIONUTRICS, INC.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Bionutrics, Inc.
(Registrant)
Dated: February 26, 1998 By: /s/ George E. Duck, Jr.
-------------------------
Its: Vice President, Finance
-------------------------
Secretary and Treasurer
-------------------------
3
